title: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
authors.forename: A A
authors.initials: AA
authors.lastname: Miller
authors.forename: R C
authors.initials: RC
authors.lastname: Lilenbaum
authors.forename: T J
authors.initials: TJ
authors.lastname: Lynch
authors.forename: G L
authors.initials: GL
authors.lastname: Rosner
authors.forename: M J
authors.initials: MJ
authors.lastname: Ratain
authors.forename: M R
authors.initials: MR
authors.lastname: Green
authors.forename: R L
authors.initials: RL
authors.lastname: Schilsky
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced*; D017239:Paclitaxel / Q000009:adverse effects; D018805:Sepsis / Q000209:etiology* / Q000276:immunology; D019772:Topotecan
chemical_list: D019772:Topotecan; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin